FIELD: chemistry.
SUBSTANCE: invention relates to biochemistry, particularly to an antibody or a fragment thereof, which specifically bind the human glucagon receptor (GCGR). Also disclosed is a polynucleotide coding said antibody; expression vector containing said polynucleotide; cell containing said vector; pharmaceutical composition containing said antibody. Disclosed is a method of producing said antibody.
EFFECT: invention makes it possible to effectively treat diseases, disorders and pathological conditions associated with high blood glucose levels.
38 cl, 7 ex, 14 tbl, 5 dwg
Title | Year | Author | Number |
---|---|---|---|
C3 BINDING AGENTS AND METHODS OF THEIR USE | 2019 |
|
RU2802307C2 |
ANTIBODIES TARGETING B-CELL MATURATION ANTIGEN AND METHODS OF THE USE THEREOF | 2015 |
|
RU2766094C2 |
MICA/B ANTIBODIES BLOCKING MICA/B SHEDDING AND METHODS OF USE THEREOF | 2019 |
|
RU2815101C2 |
MONOCLONAL ANTIBODY TO NAV1.7 | 2019 |
|
RU2776821C2 |
ANTIBODIES TO CHIMERIC ANTIGEN RECEPTORS DERIVED FROM 4G7 | 2020 |
|
RU2826051C2 |
ANTIBODIES AGAINST IL-7R ALPHA SUBUNIT AND THEIR USE | 2020 |
|
RU2811912C2 |
PROTEIN BINDING WITH NKG2D, CD16 AND WITH TUMOR-SPECIFIC ANTIGEN | 2018 |
|
RU2826991C2 |
ANTIBODIES WHICH BIND TO SORTILIN AND INHIBIT THE BINDING OF PROGRANULIN | 2016 |
|
RU2735639C2 |
ANTI-C5 ANTIBODIES AND THEIR USE | 2018 |
|
RU2774716C2 |
ADVANCED PROCOAGULANT ANTIBODIES | 2019 |
|
RU2810748C2 |
Authors
Dates
2024-06-06—Published
2018-01-26—Filed